Overview

An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Open-label safety, tolerability, pharmacokinetics and immunogenicity study in three dose escalation groups
Phase:
Phase 1
Details
Lead Sponsor:
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Treatments:
Antibodies, Monoclonal